Oncoinvent ASA (LON:0RU5)
London · Delayed Price · Currency is GBP · Price in NOK 42.50
-0.06 (-0.13%)
Feb 10, 2026, 11:47 AM GMT
Oncoinvent ASA Company Description
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer.
Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial.
The company is based in Oslo, Norway.
Oncoinvent ASA
| Country | Norway |
| Founded | 2007 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Oystein Soug |
Contact Details
Address: Gullhaugveien 7 Oslo, 0484 Norway | |
| Phone | 47 22 18 33 05 |
| Website | oncoinvent.com |
Stock Details
| Ticker Symbol | 0RU5 |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0013711713 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramzi Amri M.D., Ph.D. | Chief Executive Officer |
| Oystein Soug M.Sc | Chief Executive Officer |
| Gro Elisabeth Hjellum | Chief Operating Officer |
| Kristine Lofthus | Chief Production Officer |
| Stian Brekke | Head of Regulatory Affairs |
| Dr. Kari Myren M.D. | Chief Medical Officer |
| Anne Cecile Alvik | Head of Quality Assurance and Employee Representative Director |
| Dr. Anne-Kirsti Aksnes Ph.D. | Chief Clinical Officer |
| Froydis Schulz | Head of Health Safety and Environment |
| Kaja Tunhovd Johansen | Head of Quality Control |